[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

LT5001B - Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas - Google Patents

Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas Download PDF

Info

Publication number
LT5001B
LT5001B LT2002035A LT2002035A LT5001B LT 5001 B LT5001 B LT 5001B LT 2002035 A LT2002035 A LT 2002035A LT 2002035 A LT2002035 A LT 2002035A LT 5001 B LT5001 B LT 5001B
Authority
LT
Lithuania
Prior art keywords
mesoprogestin
estrogen
oxime
diene
methoxymethyl
Prior art date
Application number
LT2002035A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2002035A (lt
Inventor
Kristof Chwalisz
Walter Elger
Gerd Schubert
Original Assignee
Jenapharm Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jenapharm Gmbh & Co. Kg filed Critical Jenapharm Gmbh & Co. Kg
Publication of LT2002035A publication Critical patent/LT2002035A/lt
Publication of LT5001B publication Critical patent/LT5001B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LT2002035A 1999-08-31 2002-03-26 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas LT5001B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38613399A 1999-08-31 1999-08-31

Publications (2)

Publication Number Publication Date
LT2002035A LT2002035A (lt) 2002-10-25
LT5001B true LT5001B (lt) 2003-03-25

Family

ID=23524305

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2002035A LT5001B (lt) 1999-08-31 2002-03-26 Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas

Country Status (28)

Country Link
EP (1) EP1605949A2 (sl)
JP (1) JP2003511399A (sl)
KR (1) KR20020038745A (sl)
CN (1) CN1384748A (sl)
AR (1) AR025455A1 (sl)
AU (1) AU781835B2 (sl)
BG (1) BG106441A (sl)
BR (1) BR0013711A (sl)
CA (1) CA2383650A1 (sl)
CO (1) CO5190694A1 (sl)
CZ (1) CZ2002707A3 (sl)
EA (1) EA006805B1 (sl)
EE (1) EE200200103A (sl)
HR (1) HRP20020265A2 (sl)
HU (1) HUP0202515A3 (sl)
IL (1) IL148415A0 (sl)
LT (1) LT5001B (sl)
LV (1) LV12940B (sl)
MX (1) MXPA02002186A (sl)
NO (1) NO20020998L (sl)
NZ (1) NZ517470A (sl)
PE (1) PE20010579A1 (sl)
PL (1) PL353994A1 (sl)
SI (1) SI20853A (sl)
SK (1) SK2982002A3 (sl)
UA (1) UA77150C2 (sl)
WO (1) WO2001026603A2 (sl)
YU (1) YU13902A (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005539016A (ja) * 2002-08-02 2005-12-22 シエーリング アクチエンゲゼルシャフト 女性用受胎調節及びホルモン置換療法のための高められた抗ゴナドトロピン活性を有するプロゲステロン受容体モジュレーター
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
CA2524474A1 (en) * 2003-05-02 2004-11-18 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
EP1773344A1 (en) * 2004-07-07 2007-04-18 Wyeth a Corporation of the State of Delaware Cyclic progestin regimens and kits
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
BRPI1014035A2 (pt) 2009-04-14 2016-04-12 Hra Pharma Lab método para contracepção.
CN110548034A (zh) * 2019-07-12 2019-12-10 广州莎蔓生物科技有限公司 一种怀孕阻断药物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
US2156599A (en) 1936-11-20 1939-05-02 Soc Of Chemical Ind Estradiol esters esterified in 3-position and process of making same
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
WO1993023020A1 (en) 1992-05-12 1993-11-25 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
WO1994018982A1 (en) 1993-02-19 1994-09-01 The Medical College Of Hampton Roads Method of preventing or inhibiting fertilization
DE4332284A1 (de) 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398A1 (de) 1994-08-09 1996-02-15 Jenapharm Gmbh Pharmazeutische Zusammensetzungen mit Estra-1,3,5(10)-trien-Derivaten
DE4429397A1 (de) 1994-08-09 1996-02-15 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061672T3 (es) * 1987-09-24 1994-12-16 Jencap Research Ltd Preparado hormonal y su uso.
ES2279515T3 (es) * 1994-10-24 2007-08-16 Bayer Schering Pharma Aktiengesellschaft Antagonistas competitivos de la progesterona para el control de la fertilidad femenina, orientado a las necesidades de uso.
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
CZ290697B6 (cs) * 1996-06-25 2002-09-11 Akzo Nobel N. V. Systém pro perorální antikoncepci
WO1998005679A2 (en) * 1996-08-05 1998-02-12 Duke University Mixed agonists of the progesterone receptor and assays therefor
DE19809845A1 (de) * 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
WO2000066590A2 (en) * 1999-05-04 2000-11-09 Ligand Pharmaceuticals, Inc. Tetracyclic progesterone receptor modulator compounds and methods

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2054271A (en) 1932-05-17 1936-09-15 Schering Kahlbaum Ag Production of crystallized hormone esters
US2156599A (en) 1936-11-20 1939-05-02 Soc Of Chemical Ind Estradiol esters esterified in 3-position and process of making same
US2225419A (en) 1937-03-01 1940-12-17 Schering Corp Process for the conversion of 17-cisalcohols of the cyclopentanopolyhydrophenanthrene series into the corresponding 17-trans-alcohols
US2611773A (en) 1951-08-21 1952-09-23 Upjohn Co Estradiol 17-cyclopenetanepropionate
US2990414A (en) 1957-03-26 1961-06-27 Syntex Sa 17-undecenoate of estradiol
DE3337450A1 (de) 1983-10-12 1985-04-25 Schering AG, 1000 Berlin und 4709 Bergkamen Prostaglandine und antigestagene fuer den schwangerschaftsabbruch
WO1993023020A1 (en) 1992-05-12 1993-11-25 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
WO1994018982A1 (en) 1993-02-19 1994-09-01 The Medical College Of Hampton Roads Method of preventing or inhibiting fertilization
DE4332284A1 (de) 1993-09-20 1995-03-23 Jenapharm Gmbh Neue 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4429398A1 (de) 1994-08-09 1996-02-15 Jenapharm Gmbh Pharmazeutische Zusammensetzungen mit Estra-1,3,5(10)-trien-Derivaten
DE4429397A1 (de) 1994-08-09 1996-02-15 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
COLLINS, R.L., HODGEN, G.D.: "Blockade of spontaneous midcycle gonadotropin surge in monkeys by RU 486: a progesterone antagonist or agonist?", J. CLIN. ENDOCRINOL. METAB., 1986, pages 1270 - 1276
DANFORTH DR, DUBOIS C, ULMANN A, BAULIEU EE,: "Contraceptive potential of RU 486 by ovulation inhibition: III. Preliminary observations on once weekly oral administration", CONTRACEPTION, 1989, pages 195 - 200, XP026183142, DOI: doi:10.1016/0010-7824(89)90006-1
ELGER W ET AL.: "Sulfamates of various estrogens are prodrugs with increased systemic and reduced hepatic estrogenicity at oral application", J STEROID BIOCHEM MOL BIOL., 1995, pages 395 - 403, XP005348960, DOI: doi:10.1016/0960-0760(95)00214-6
ELGER W, BEIER S ET AL.: "Studies on the mechanisms of action of progesterone antagonists", J STEROID BIOCHEM., 1986, pages 835 - 845, XP023414415, DOI: doi:10.1016/0022-4731(86)90314-6
H. SELYE ET AL.: "Textbook of Endocrinology", pages: 345 - 346
LIU JH, GARZO G, MORRIS S, STUENKEL C, ULMANN: "Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486", J CLIN ENDOCRINOL METAB., 1987, pages 1135 - 1140
LUUKKAINEN T ET AL.: "Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486", FERTIL STERIL., 1988, pages 961 - 963, XP002189879
M. B. ZELINSKI-WOOTEN ET AL.: "Chronic treatment of female cycling rhesus monkeys with low-dosesof the antiprogestin ZK 137316: Establishment of a regiment that permits normal menstrual cyclicity", HUM. REPROD., 1998, pages 256 - 267
M.L. SWAHN ET AL.: "The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium", HUM. REPROD., 1990, pages 402 - 408, XP008002480
P. F. VAN LOOK ET AL.: "Antiprogestational steroids: A new dimension in human fertility regulation", OXFORD REVIEWS OF REPRODUCTIVE BIOLOGY, 1989, pages 2 - 60
SHETH A ET AL.: "A randomized, double-blind study of two combined and two progestogen-only oral contraceptives", CONTRACEPTION, 1982, pages 243, XP023168910, DOI: doi:10.1016/0010-7824(82)90047-6
SHOUPE D ET AL.: "Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase", AM J OBSTET GYNECOL., 1987, pages 1421 - 1426
W. ELGER ET AL.: "Endometrial and myometrial effects of progesterone antagonists in pregnant guinea pigs", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1987, pages 1065 - 1074

Also Published As

Publication number Publication date
EA006805B1 (ru) 2006-04-28
CA2383650A1 (en) 2001-04-19
BG106441A (bg) 2002-09-30
LT2002035A (lt) 2002-10-25
EP1605949A2 (en) 2005-12-21
WO2001026603A3 (en) 2002-01-17
SI20853A (sl) 2002-10-31
NO20020998L (no) 2002-03-14
SK2982002A3 (en) 2002-07-02
PL353994A1 (en) 2003-12-15
MXPA02002186A (es) 2002-09-02
HUP0202515A2 (hu) 2002-12-28
PE20010579A1 (es) 2001-06-04
CN1384748A (zh) 2002-12-11
CO5190694A1 (es) 2002-08-29
HUP0202515A3 (en) 2004-06-28
KR20020038745A (ko) 2002-05-23
UA77150C2 (en) 2006-11-15
EA200200284A1 (ru) 2002-10-31
WO2001026603A2 (en) 2001-04-19
EE200200103A (et) 2003-04-15
BR0013711A (pt) 2002-05-07
NZ517470A (en) 2004-03-26
JP2003511399A (ja) 2003-03-25
AU781835B2 (en) 2005-06-16
NO20020998D0 (no) 2002-02-28
YU13902A (sh) 2006-01-16
AR025455A1 (es) 2002-11-27
IL148415A0 (en) 2002-09-12
CZ2002707A3 (cs) 2002-11-13
HRP20020265A2 (en) 2004-02-29
AU3215001A (en) 2001-04-23
LV12940B (en) 2003-06-20

Similar Documents

Publication Publication Date Title
CZ195397A3 (en) Progesteron antagonistically and antiestrogenic active compounds for common use for woman contraception
PT787002E (pt) Antagonistas de progesterona competitivos para controlo de fertilidade feminina orientado pela necessidade
LT5001B (lt) Mezoprogestinai (progesterono receptoriaus moduliatoriai) kaip moterų kontraceptikų komponentas
LT5034B (lt) Mezoprogestinai (progesteroninių receptorių moduliatoriai), skirti hormonų sąlygotų gėrybinių ginekologinių sutrikimų gydymui ir prevencijai
KR100729311B1 (ko) 호르몬 대체 요법(ｈｒｔ)용 조성물의 성분으로서의메조프로게스틴 (프로게스테론 수용체 조절물질)
HU221162B1 (en) Use of antiprogestin for preparing pharmaceutical compositions preventing or inhibiting the fertilization
ZA200201614B (en) Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives.
US7629334B1 (en) Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)

Legal Events

Date Code Title Description
PC9A Transfer of patents

Owner name: SCHERING AKTIENGESELLSCHAFT, DE

Effective date: 20030513

MM9A Lapsed patents

Effective date: 20080831